Background: Few percutaneous coronary intervention (PCI) patients achieve low-density lipoprotein cholesterol (LDL-C) targets with statins alone. While proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors effectively diminish LDL-C levels, their combined use with statins for reducing major adverse cardiovascular events (MACE) and improving lipid profiles post-PCI requires further validation. This study seeks to appraise the therapeutic impact of PCSK9 inhibitors combined with statins on MACE and blood lipids in patients following PCI. Methods: Randomized controlled trials (RCTs) and cohort studies as of February 2025 in the PubMed, Embase, Cochrane Library, and Web of Science databases were identified. Regarding the risk of bias evaluation, Cochrane ROB 2.0 was employed for RCTs. Moreover, cohort studies were appraised by means of the Newcastle-Ottawa Scale. In terms of heterogeneity, it was appraised by means of the I2 statistics. The relative risk (RR) and 95% confidence interval (CI) for dichotomous variables, along with the weighted mean difference (WMD), standardized mean difference (SMD), and their respective 95% CIs for continuous variables. Results: The meta-analysis included 17 studies, including 9 RCTs and 8 cohort studies, involving 5,607 subjects. The meta-analysis revealed that, against the statin group, the combination therapy group displayed a notable decline in MACE incidence (RR: 0.61; 95% CI: 0.50–0.75; p < 0.001; I2 = 0.0%). Meanwhile, the combination therapy group demonstrated greater LDL-C reduction vs. statin monotherapy (SMD: −1.29; 95% CI: −1.70 to −0.87). Moreover, The combination therapy group achieved significantly higher LDL-C ≤ 1.4 mmol/L attainment rates vs. statin monotherapy (RR: 5.83; 95% CI: 5.20–6.55). Conclusion: PCSK9 inhibitors combined with statins significantly reduces MACE incidence, improves lipid profiles in post-PCI patients compared to statin monotherapy. Systematic Review Registration: https://www.crd.york.ac.uk/ , identifier (CRD420250650716).
20 August 2025 in Reviews in Cardiovascular Medicine
Background: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score represents a meaningful predictor in many cardiovascular diseases. However, the predictive utility of this score for the outcome of patients admitted to the intensive care unit (ICU) due to acute myocardial infarction (AMI) has yet to be fully elucidated. Methods: Information from the Medical Information Mart for Intensive Care (MIMIC)-IV v3.1 database was used to analyze the association between the HALP score and 90 days and 365 days all-cause mortality in critically ill patients with AMI. Patients were grouped according to the calculated HALP quartiles. Cox proportional hazards regression analysis and restricted cubic spline (RCS) analysis were performed to assess the association between the HALP score and mortality risk. A recursive algorithm identified the HALP inflection point, thus defining high and low HALP groups for the Kaplan–Meier survival analysis. Subgroup analyses analyzed the robustness across clinical strata. Furthermore, predictive models based on machine learning algorithms that included the HALP score were constructed to estimate 90 days mortality. The performance of the models was evaluated using the area under the receiver operating characteristic curve (AUC). Results: A total of 818 AMI patients were included. The analysis revealed mortality rates of 31% at 90 days and 40% at 365 days. Elevated HALP values were independently linked to a reduced risk of death. In fully adjusted models, patients in the top HALP quartile exhibited significantly lower all-cause mortality at 90 days (hazard ratio (HR) = 0.68; 95% confidence interval (CI): 0.47–0.99; p = 0.047) and 365 days (HR = 0.66; 95% CI: 0.47–0.90; p = 0.011). A nonlinear, inverse “L-shaped” association was observed, with an inflection point identified at a HALP value of 19.41. Below this value, each unit increase in the HALP score reduced mortality risk by 2.4%–2.7%. The Kaplan–Meier curves confirmed an improved survival above the threshold. Meanwhile, the subgroup analyses revealed a generally consistent association between the HALP score and mortality, except for age, where a significant interaction was observed (p = 0.003), indicating a stronger protective effect in older patients. Machine learning analyses supported the robustness and predictive value of the HALP score, with a maximum AUC of 0.7804. Conclusions: The HALP score is significantly associated with all-cause mortality among critically ill individuals suffering from AMI.
23 October 2025 in Frontiers in Cardiovascular Medicine
Background: The platelet-albumin-bilirubin (PALBI) score has shown prognostic value across multiple medical conditions; nevertheless, its effectiveness in forecasting prognoses among severely ill heart failure (HF) patients treated in Intensive Care Unit (ICU) has yet to be fully established. This study explores the relationship between PALBI scores at ICU admission and all-cause mortality in HF patients admitted to the ICU. Methods: Drawing on records from the MIMIC-IV version 3.1 critical care database, we included ICU-admitted HF patients and calculated their PALBI scores at admission. Kaplan–Meier survival curves and log-rank tests were used to assess differences in overall mortality at 30 and 360 days across the PALBI tertile groups. Cox regression models based on the proportional hazards assumption were utilized to control for possible confounding variables. In addition, predictive models based on machine learning were constructed using PALBI alongside other clinical features to estimate 30-day mortality, with model performance evaluated through the area under the ROC curve (AUC). Results: A total of 4,318 participants were included in the study cohort (57% male; median age 73 years). The cumulative incidence of all-cause mortality was 24% at 30 days and 44% at 360 days. Individuals in the top PALBI tertile exhibited markedly higher mortality rates compared to those in the lowest tertile (30% vs. 20% at 30 days and 52% vs. 39% at 360 days). Multivariate Cox regression analysis revealed significant associations of elevated PALBI scores with higher mortality risk at both 30 days (HR: 1.36; 95% CI: 1.12–1.64; p= 0.002) and 360 days (HR: 1.22; 95% CI: 1.03–1.44; p= 0.019). Machine learning models effectively discriminated patients at risk of 30-day mortality, with the best performance achieved by Ridge regression (AUC = 0.76). Conclusion: The PALBI score independently predicts 30-day and 360-day all-cause mortality among ICU-admitted HF patients. These findings suggest that the PALBI score has potential utility for risk stratification and for guiding treatment decisions in the intensive care management of HF.
19 December 2025 in Frontiers in Cardiovascular Medicine
Background: Although the neutrophil percentage-to-albumin ratio (NPAR) has shown prognostic value in multiple clinical conditions, its prognostic accuracy for myocardial infarction (MI) patients receiving intensive care has yet to be clearly defined. To our knowledge, this study is the first to comprehensively evaluate the prognostic role of NPAR in ICU-admitted MI patients, integrating both conventional Cox regression and machine learning approaches to address an existing gap between general MI cohorts and critically ill populations. Method: Using data from the MIMIC-IV v3.1 database, we retrospectively included 1,759 ICU-admitted MI patients and calculated NPAR at admission. Primary and secondary outcomes were 30-day and 360-day all-cause mortality, respectively. Kaplan–Meier curves and log-rank tests compared survival across tertiles. Multivariate Cox models assessed associations, with restricted cubic splines evaluating nonlinearity. Machine learning models incorporating NPAR were developed to predict 30-day mortality, and model performance was assessed using the area under the receiver operating characteristic curve (AUC). Result: The 30-day and 360-day all-cause mortality rates were 24% and 38%, respectively. Kaplan–Meier analysis revealed significantly lower survival probabilities in patients with higher NPAR levels. Adjusted Cox regression showed that those in the highest NPAR tertile had an increased risk of 30-day (HR: 2.03, 95% CI: 1.51–2.73, p < 0.001) and 360-day (HR: 1.81, 95% CI: 1.45–2.26, p < 0.001) mortality. Machine learning models incorporating NPAR achieved an AUC of up to 0.81 for predicting 30-day death. Conclusion: The NPAR serves as an independent predictor of mortality at 30 and 360 days in MI patients admitted to the intensive care unit (ICU). When integrated into machine learning models, NPAR enhances predictive accuracy. These results indicate that NPAR serves as an independent predictor of short- and long-term mortality in ICU-admitted MI patients. Given its simplicity and accessibility from routine laboratory tests, NPAR can be feasibly incorporated into clinical decision-making and risk stratification protocols in critical care settings to facilitate individualized risk assessment and improve outcomes.
East Asian patients with acute coronary syndrome (ACS) are more prone to bleeding complications than Western populations under comparable antithrombotic re